Mesoblast stock set for board refresh as two directors depart

Mesoblast plans a board refresh as it shifts its focus toward commercial growth following the US launch of Ryoncil. The company announced the changes on November 1, 2026, in a release carried by Yahoo Finance.

Board changes support commercial expansion

William Burns will retire at Mesoblast's 2026 annual general meeting after serving on the board since 2014. Philip Krause will also retire after joining the board in 2022. Jane Bell AM will take over as chair of the Nomination and Remuneration Committee.

Chair Philip Facchina said Mesoblast is now a revenue-generating commercial enterprise after the Ryoncil launch in the United States. The company plans to recruit directors with US and global commercial expertise in the biopharmaceutical sector, linking the board changes to its next phase of commercial delivery and growth.

Ryoncil remains the commercial anchor

Ryoncil is approved for pediatric patients aged two months and older with steroid-refractory acute graft-versus-host disease. Mesoblast is also developing the therapy for adult disease and biologic-resistant inflammatory bowel disease, while rexlemestrocel-L programs target heart failure and chronic low back pain.

Mesoblast stock traded at 1.38 euros on Lang & Schwarz at 20:52 CET on Tuesday, November 3, 2026. Investors can follow the real-time quote of Mesoblast stock.

Mesoblast Limited at a glance

• ISIN: AU000000MSB8
• WKN: A0DNPW
• Listings: Nasdaq: MESO; ASX: MSB
• Lang & Schwarz quote: 1.38 euros at 20:52 CET on November 3, 2026

The broader Australian market is tracked in the S&P/ASX 200.

More news and analyses on Mesoblast stock are available in the company overview.